Aro Biotherapeutics

About:

Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.

Website: https://www.arobiotx.com

Twitter/X: AroBioTx

Top Investors: Ionis Pharmaceuticals, Biotechnology Value Fund, Northpond Ventures, BioMotiv, HealthCap

Description:

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.